drugset / Trial / NCT02886065
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Phase 1
Active not recruiting
19 enrolled
Massachusetts General Hospital
Celgene Corporation · collabOncoPep, Inc. · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: * Lenalidomide * Citarinostat (CC-96241) * PVX-410
Timeline
- Start
- 2017-03-07
- Primary completion
- 2026-09-15
- Completion
- 2026-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Citarinostat | Small molecule | 180 mg | Oral |
| Subject | Hiltonol | Other / unclassified | 1 mg | Intramuscular |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | PVX-410 | Vaccine | 0.8 mg | Subcutaneous |